Summary
The FDA approved the first oral pill for weight loss from Novo Nordisk, called Wegovy. This pill, a type of drug known as GLP-1, will be available in early January and aims to be a more convenient and affordable alternative to the injectable version.
Key Facts
- The FDA approved the first pill form of Novo Nordisk's weight-loss drug Wegovy.
- The pill is a daily medication and will be available in early January.
- The starting dose of the pill will cost $149 per month.
- In a 64-week trial, participants using the pill lost an average of 17% of their weight.
- The active ingredient for the pill will be made in North Carolina.
- Novo Nordisk competes with Eli Lilly in the anti-obesity market.
- The pill offers a more convenient option for those who prefer not to use injections.
- The company plans to ensure the pill's availability to prevent shortages.
